• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oragenics Inc. Common Stock (NY:OGEN)

0.8405 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oragenics Inc. Common Stock

< Previous 1 2 3 Next >
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial
February 02, 2026
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sequire Investor Summit 2026
January 14, 2026
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Advances Toward First Clinical Trial and Expands AI-Driven Neurology Pipeline
November 12, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Oragenics Q3 2025 Shareholder Update
November 12, 2025
From Oragenics, Inc.
Via Business Wire
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Strengthens Balance Sheet for Clinical Advancement
October 21, 2025
Via Investor Brand Network
News headline image
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
October 21, 2025
From Oragenics, Inc.
Via Business Wire
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics
October 07, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
October 07, 2025
From Oragenics
Via Business Wire
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Q2 2025 Progress and Prepares for Phase IIa Concussion Trial
August 11, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Selects Southern Star Research as CRO for Phase IIa Trial of Intranasal Concussion Therapy ONP-002
July 31, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures U.S. Manufacturing Partner Ahead of Phase IIb Trials for Concussion Drug
July 16, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures $16.5 Million in Preferred Stock Offering to Advance Intranasal Concussion Therapy
July 03, 2025
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Announces $20 Million Preferred Stock and Warrant Offering
July 01, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Spotlight Concussion Candidate at BIO 2025 and Neurotrauma Symposium
June 10, 2025
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Sets 1-for-30 Reverse Stock Split Effective June 3
May 28, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures Australian Approval to Launch Phase II Concussion Trial
May 13, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Host May 20 Webinar on Concussion Drug Program ONP-002
May 12, 2025
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Submits Protocol for Phase II Concussion Trial in New Zealand
April 09, 2025
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Intranasal Drug Delivery at Boston Summit
April 08, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. Highlights Q1 Milestones and Prepares for Concussion Drug Trial
March 27, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status
March 19, 2025
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. Advances Concussion Treatment with Phase II Trial Preparation
March 06, 2025
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Highlights Concussion Treatment Advances at Emergencies in Medicine Conference
February 25, 2025
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Appoints Chief Medical Officer to Medical Board of The Leigh Steinberg Foundation
February 24, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Partners With BRAINBox Solutions to Advance Concussion Care
February 11, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Chief Medical Officer to Speak at Brain Health Summit During Super Bowl Week
February 05, 2025
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Advances ONP-002 Development, Appoints Janet Huffman as Interim CEO
January 21, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Streamlines Capital Structure with Preferred Stock Conversion
December 16, 2024
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Oragenics to Present at Centurion One Capital 2nd Annual Bahamas Summit
October 18, 2024
Via Investor Brand Network
BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment
October 09, 2024
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap